Ibrutinib is a first-in-class, once-daily covalent inhibitor of Bruton’s tyrosine kinase (BTK) approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease following the failure of 1 or more lines of systemic therapy [7]. Here, BTK is linked to chronic graft versus host disease.